0808 800 6000

Contact our nurses

  • Researchers
  • Healthcare professionals
  • Login
  • Basket
    0
Breast Cancer Now logo
Donate
Menu Browse
  • Support for you
    • About breast cancer

      • Signs and symptoms of breast cancer
      • Primary breast cancer
      • Secondary breast cancer
      • Diagnosis
      • Treatment
      • Life after treatment
      • Download and order publications
    • Support for you

      Our free courses, events and one-to-one support are a chance to meet people who understand and get the support you need.

      • Ask our nurses a question

        Use our free nurse helpline or email our nurses a question
      • Join our forum

        Share your experiences, ask questions and chat to people who understand
  • Our research
    • Our research

      • About our research
      • Research centres and projects
      • Research achievements
    • Information for researchers

      • Funding opportunities
      • Participate in a research study

      • Research news

  • Get involved
    • Get involved

      • Wear It Pink
      • Fundraising events
      • Do your own fundraising
      • Volunteer with us
      • Campaign with us
      • Special events
    • Donate

      • Make a donation
      • Leave a gift in your will
      • Giving in memory
      • Play our weekly lottery
      • Philanthropy and charitable trusts
      • Partner with us
      • Wear it pink this October

        At work. At school. At home. Wherever you do it, wear pink and raise money to fund life-changing research and support
  • About us
    • About us

      • Why we do it
      • Who we are
      • News and blogs
      • Developing policy
    • Media

      • Press releases
      • Media statements
      • Careers

      • Contact us

  • Popular searches

    _BCN0247_HCP_CHELTENHAM_THIRLESTANE_2022.jpg

    About breast cancer

    A woman at a table, holding a hot drink

    Support for you

    TISSUEBANK_2022_BCN3183.jpg

    Our research

  • Researchers
  • Healthcare professionals
  • Login
  • Basket
Donate
Home
Research Catalogue Analytics Hub Biobank Samples
The Cancer Genome Atlas (TCGA) International Cancer Genome Consortium (ICGC) The Cancer Cell Line Encyclopedia (CCLE)
Genomics England (GEL) Spatial Characterisation
User Guide
  1. Publicly Available Data

International Cancer Genome Consortium
Korean Cohort

Powered by SNPnexus


Summary
Clinical Summary Genomics Cohort Browser Details
Overview Help
Sex
Survival Status
Age at Diagnosis
Loading...
Cohort Summary Variant Identification Drug Prediction Interactions & Pathways
Help
Genomics Summary
Oncoplot help
Oncoplot
LolliPlot help
Loading...
LolliPlot
Somatic Interactions help
Somatic Interactions
TCGA Compare help
TCGA Compare
Cancer Genome Interpreter (CGI) help
CGI Biomarker CGI Bioactivity
Gene Protein Alteration Alteration Match Drug Effect Tumour Evidence
KMT2A MLL MUT* (intron_variant) Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A MLL MUT* (intron_variant) Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A MLL MUT* (intron_variant) Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A MLL MUT* (intron_variant) Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A MLL MUT* (intron_variant) Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A MLL MUT* (intron_variant) Different Alteration DOT1L inhibitor Responsive AML Early trials
NOTCH2 NOTCH2 MUT* (S851S) Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
PIK3CA PIK3CA MUT (H1047R) Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA PIK3CA MUT (H1047R) Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA PIK3CA MUT (H1047R) Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA PIK3CA MUT (H1047R) Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA PIK3CA MUT (H1047R) Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA PIK3CA MUT (H1047R) Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA PIK3CA MUT (H1047R) Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA PIK3CA MUT (H1047R) Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA PIK3CA MUT (H1047R) Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA PIK3CA MUT (H1047R) Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA PIK3CA MUT (H1047R) Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA PIK3CA MUT (H1047R) Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA PIK3CA MUT (H1047R) Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA PIK3CA MUT (H1047R) Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
RAF1 RAF1 MUT* (intron_variant) Different Alteration Sorafenib (Pan-TK inhibitor) Responsive PRAD Pre-clinical
RAF1 RAF1 MUT* (intron_variant) Different Alteration Pan-RAF inhibitor Responsive PRAD Pre-clinical
RAF1 RAF1 MUT* (intron_variant) Different Alteration U0126 (MEK inhibitor) Responsive PRAD Pre-clinical
TP53 TP53 MUT (Q165*) Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 TP53 MUT (Q165*) Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 TP53 MUT (Q165*) Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 TP53 MUT (Q165*) Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 TP53 MUT (Q165*) Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 TP53 MUT (Q165*) Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 TP53 MUT (Q165*) Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (Q165*) Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (Q165*) Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 TP53 MUT (Q165*) Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 TP53 MUT (Q165*) Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 TP53 MUT (Q165*) Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (Q165*) Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 TP53 MUT (Q165*) Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (Q165*) Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
AKT1 AKT1 MUT (E17K) Complete Match BRAF inhibitor Resistant CM Case report
AKT1 AKT1 MUT (E17K) Complete Match allosteric AKT inhibitor Responsive CANCER Early trials
AKT1 AKT1 MUT (E17K) Complete Match non-allosteric AKT inhibitor Responsive CANCER Early trials
AKT1 AKT1 MUT (E17K) Complete Match PI3K pathway inhibitor Responsive HNSC Case report
AKT1 AKT1 MUT (E17K) Complete Match Temsirolimus (MTOR inhibitor) Responsive ED Early trials
AKT1 AKT1 MUT (E17K) Complete Match AKT inhibitor Responsive CANCER Pre-clinical
AKT1 AKT1 MUT (E17K) Different Mutation Everolimus (MTOR inhibitor) Responsive FH Case report
NTRK3 NTRK3 MUT* (R459W) Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 NTRK3 MUT* (R459W) Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 NTRK3 MUT* (R459W) Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
TP53 TP53 MUT (G244C) Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 TP53 MUT (G244C) Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 TP53 MUT (G244C) Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 TP53 MUT (G244C) Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 TP53 MUT (G244C) Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 TP53 MUT (G244C) Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 TP53 MUT (G244C) Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (G244C) Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (G244C) Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 TP53 MUT (G244C) Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 TP53 MUT (G244C) Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 TP53 MUT (G244C) Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (G244C) Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 TP53 MUT (G244C) Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (G244C) Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PIK3CA PIK3CA MUT (H1047L) Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA PIK3CA MUT (H1047L) Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA PIK3CA MUT (H1047L) Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA PIK3CA MUT (H1047L) Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA PIK3CA MUT (H1047L) Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA PIK3CA MUT (H1047L) Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA PIK3CA MUT (H1047L) Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA PIK3CA MUT (H1047L) Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA PIK3CA MUT (H1047L) Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA PIK3CA MUT (H1047L) Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA PIK3CA MUT (H1047L) Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA PIK3CA MUT (H1047L) Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA PIK3CA MUT (H1047L) Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA PIK3CA MUT (H1047L) Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
MET MET MUT* (A48A) Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
NOTCH2 NOTCH2 MUT* (A3S), NOTCH2 MUT* (A3V) Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
TP53 TP53 MUT (H193R) Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 TP53 MUT (H193R) Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 TP53 MUT (H193R) Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 TP53 MUT (H193R) Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 TP53 MUT (H193R) Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 TP53 MUT (H193R) Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 TP53 MUT (H193R) Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (H193R) Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (H193R) Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 TP53 MUT (H193R) Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 TP53 MUT (H193R) Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 TP53 MUT (H193R) Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (H193R) Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 TP53 MUT (H193R) Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (H193R) Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NOTCH2 NOTCH2 MUT* (5-UTRSNV) Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
TP53 TP53 MUT (G199V) Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 TP53 MUT (G199V) Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 TP53 MUT (G199V) Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 TP53 MUT (G199V) Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 TP53 MUT (G199V) Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 TP53 MUT (G199V) Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 TP53 MUT (G199V) Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (G199V) Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (G199V) Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 TP53 MUT (G199V) Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 TP53 MUT (G199V) Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 TP53 MUT (G199V) Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (G199V) Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 TP53 MUT (G199V) Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (G199V) Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NOTCH2 NOTCH2 MUT* (5-UTRSNV), NOTCH2 MUT* (intron_variant) Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
GATA3 GATA3 MUT (splice_donor_variant) Complete Match Aromatase ihibitor Responsive BRCA Pre-clinical
PIK3CA PIK3CA MUT (C420R) Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA PIK3CA MUT (C420R) Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA PIK3CA MUT (C420R) Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA PIK3CA MUT (C420R) Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA PIK3CA MUT (C420R) Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA PIK3CA MUT (C420R) Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA PIK3CA MUT (C420R) Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA PIK3CA MUT (C420R) Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA PIK3CA MUT (C420R) Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA PIK3CA MUT (C420R) Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA PIK3CA MUT (C420R) Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA PIK3CA MUT (C420R) Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA PIK3CA MUT (C420R) Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA PIK3CA MUT (C420R) Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
PIK3CA PIK3CA MUT (E542K) Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA PIK3CA MUT (E542K) Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA PIK3CA MUT (E542K) Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA PIK3CA MUT (E542K) Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA PIK3CA MUT (E542K) Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA PIK3CA MUT (E542K) Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA PIK3CA MUT (E542K) Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA PIK3CA MUT (E542K) Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA PIK3CA MUT (E542K) Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA PIK3CA MUT (E542K) Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA PIK3CA MUT (E542K) Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA PIK3CA MUT (E542K) Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA PIK3CA MUT (E542K) Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA PIK3CA MUT (E542K) Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
ABL1 ABL1 MUT* (A922V), ABL1 MUT* (E921D) Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
ABL1 ABL1 MUT* (A922V), ABL1 MUT* (E921D) Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ABL1 ABL1 MUT* (A922V), ABL1 MUT* (E921D) Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
ABL1 ABL1 MUT* (A922V), ABL1 MUT* (E921D) Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
ABL1 ABL1 MUT* (A922V), ABL1 MUT* (E921D) Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
ABL1 ABL1 MUT* (A922V), ABL1 MUT* (E921D) Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
TP53 TP53 MUT (R175H) Complete Match HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 TP53 MUT (R175H) Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 TP53 MUT (R175H) Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 TP53 MUT (R175H) Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 TP53 MUT (R175H) Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 TP53 MUT (R175H) Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 TP53 MUT (R175H) Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (R175H) Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (R175H) Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 TP53 MUT (R175H) Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 TP53 MUT (R175H) Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 TP53 MUT (R175H) Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (R175H) Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 TP53 MUT (R175H) Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (R175H) Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NRG1 NRG1 MUT* (intron_variant) Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 NRG1 MUT* (intron_variant) Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
RET RET MUT* (A8A) Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET RET MUT* (A8A) Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET RET MUT* (A8A) Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET RET MUT* (A8A) Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET RET MUT* (A8A) Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET RET MUT* (A8A) Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET RET MUT* (A8A) Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET RET MUT* (A8A) Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET RET MUT* (A8A) Different Alteration RET inhibitor Responsive TH Pre-clinical
PDGFB PDGFB MUT* (L11V) Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive DFS FDA guidelines
TP53 TP53 MUT (Y220C) Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 TP53 MUT (Y220C) Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 TP53 MUT (Y220C) Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 TP53 MUT (Y220C) Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 TP53 MUT (Y220C) Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 TP53 MUT (Y220C) Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 TP53 MUT (Y220C) Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (Y220C) Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (Y220C) Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 TP53 MUT (Y220C) Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 TP53 MUT (Y220C) Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 TP53 MUT (Y220C) Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (Y220C) Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 TP53 MUT (Y220C) Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (Y220C) Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 TP53 MUT (C135W) Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 TP53 MUT (C135W) Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 TP53 MUT (C135W) Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 TP53 MUT (C135W) Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 TP53 MUT (C135W) Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 TP53 MUT (C135W) Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 TP53 MUT (C135W) Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (C135W) Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 TP53 MUT (C135W) Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 TP53 MUT (C135W) Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 TP53 MUT (C135W) Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 TP53 MUT (C135W) Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (C135W) Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 TP53 MUT (C135W) Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 TP53 MUT (C135W) Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
SETD2 SETD2 MUT (R424*) Complete Match WEE1 inhibitor Responsive CANCER Pre-clinical
SETD2 SETD2 MUT (R424*) Different Alteration WEE1 inhibitor Responsive CANCER Pre-clinical
SF3B1 SF3B1 MUT (K700E) Complete Match Spliceosome inhibitor Responsive CANCER Pre-clinical
ARID1A ARID1A MUT (Q152*) Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A ARID1A MUT (Q152*) Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A ARID1A MUT (Q152*) Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A ARID1A MUT (Q152*) Complete Match ATR inhibitor Responsive CANCER Pre-clinical
EGFR EGFR MUT* (T629T) Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR EGFR MUT* (T629T) Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
ABL1 ABL1 MUT* (T729T) Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
ABL1 ABL1 MUT* (T729T) Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ABL1 ABL1 MUT* (T729T) Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
ABL1 ABL1 MUT* (T729T) Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
ABL1 ABL1 MUT* (T729T) Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
ABL1 ABL1 MUT* (T729T) Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
PML PML MUT* (intron_variant) Different Alteration Volasertib (PLK1 inhibitor) Responsive AML Early trials
PML PML MUT* (intron_variant) Different Alteration Tretinoin (Retinoid) Responsive APML FDA guidelines
PML PML MUT* (intron_variant) Different Alteration Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) Responsive AML FDA guidelines
RET RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) Different Alteration RET inhibitor Responsive TH Pre-clinical
KMT2A MLL MUT* (N3797N) Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A MLL MUT* (N3797N) Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A MLL MUT* (N3797N) Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A MLL MUT* (N3797N) Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A MLL MUT* (N3797N) Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A MLL MUT* (N3797N) Different Alteration DOT1L inhibitor Responsive AML Early trials
NTRK1 NTRK1 MUT* (A629A) Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 NTRK1 MUT* (A629A) Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 NTRK1 MUT* (A629A) Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 NTRK1 MUT* (A629A) Different Alteration Pan-TK inhibitor Responsive COREAD Case report
EGFR EGFR MUT* (intron_variant) Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR EGFR MUT* (intron_variant) Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
JAK2 JAK2 MUT* (H163H) Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
ROS1 ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
MET MET MUT* (P1382P), MET MUT* (D1304D), MET MUT* (intron_variant), MET MUT* (A1357A) Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
NOTCH1 NOTCH1 MUT* (P284P) Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 NOTCH1 MUT* (P284P) Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
ERBB4 ERBB4 MUT* (intron_variant) Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration ALK inhibitor Responsive COREAD Case report
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK ALK MUT* (G845G), ALK MUT* (intron_variant) Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
PDGFRA PDGFRA MUT* (intron_variant) Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive MDPS, MDS, ECL, HES FDA guidelines
FGFR3 FGFR3 MUT* (intron_variant), FGFR3 MUT* (N294N) Different Alteration FGFR inhibitor Responsive BLCA Case report
FGFR3 FGFR3 MUT* (intron_variant), FGFR3 MUT* (N294N) Different Alteration FGFR inhibitor Responsive G Early trials
FGFR3 FGFR3 MUT* (intron_variant), FGFR3 MUT* (N294N) Different Alteration FGFR inhibitor Responsive NSCLC Pre-clinical
TMPRSS2 TMPRSS2 MUT* (intron_variant) Different Alteration DNA-PKc inhibitor Responsive PRAD Pre-clinical
TMPRSS2 TMPRSS2 MUT* (intron_variant) Different Alteration PARP inhibitor Responsive PRAD Pre-clinical
BCR BCR MUT* (P312P) Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
BCR BCR MUT* (P312P) Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
BCR BCR MUT* (P312P) Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR BCR MUT* (P312P) Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR BCR MUT* (P312P) Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
BCR BCR MUT* (P312P) Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
EGFR EGFR MUT* (D994D) Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR EGFR MUT* (D994D) Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
PDGFRA PDGFRA MUT* (V84V) Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive MDPS, MDS, ECL, HES FDA guidelines
STK11 STK11 MUT (splice_donor_variant) Different Mutation Everolimus (MTOR inhibitor) Responsive PA Case report
STK11 STK11 MUT (splice_donor_variant) Complete Match Phenformin (Anti-diabetic) Responsive LUAD Pre-clinical
STK11 STK11 MUT (splice_donor_variant) Complete Match MTOR inhibitor Responsive CANCER Pre-clinical
STK11 STK11 MUT (splice_donor_variant) Complete Match BET inhibitor Resistant L Pre-clinical
STK11 STK11 MUT (splice_donor_variant) Complete Match PD1 inhibitor Resistant CANCER Early trials
STK11 STK11 MUT (splice_donor_variant) Complete Match SRC inhibitor;PI3K/MEK inhibitor Responsive LUAD Pre-clinical
STK11 STK11 MUT (splice_donor_variant) Complete Match MEK inhibitor Responsive LUAD Pre-clinical
STK11 STK11 MUT (splice_donor_variant) Different Alteration MTOR inhibitor Responsive CANCER Pre-clinical
STK11 STK11 MUT (splice_donor_variant) Different Alteration PD1 inhibitor Resistant CANCER Early trials
STK11 STK11 MUT (splice_donor_variant) Different Alteration Phenformin (Anti-diabetic) Responsive LUAD Pre-clinical
STK11 STK11 MUT (splice_donor_variant) Different Alteration MEK inhibitor Responsive LUAD Pre-clinical
STK11 STK11 MUT (splice_donor_variant) Different Alteration SRC inhibitor;PI3K/MEK inhibitor Responsive LUAD Pre-clinical
Variation Gene Transcript Protein Alteration Consequence Tumour Driver Oncogenic Classification
Loading...
Cancer Genome Interpreter (CGI)
Drug-Gene Interactions help

Druggable categories in the cohort

No meaningful categories found

Drug-Gene Interactions

Focus the search to a gene of interest:

Loading...
Gene Interaction Source Interaction Types Drug Claim Primary Name Drug Name ChEMBL ID
PIK3CA MyCancerGenome inhibitor INK-1117 INK-1117 CHEMBL3545055
PIK3CA CKB MS417
PIK3CA CIViC RAPAMYCIN (SIROLIMUS) SIROLIMUS CHEMBL413
PIK3CA CGI Chemotherapy
PIK3CA CKB Olaparib OLAPARIB CHEMBL521686
PIK3CA GuideToPharmacologyInteractions inhibitor HS-173
PIK3CA CKB Linsitinib LINSITINIB CHEMBL1091644
PIK3CA CKB ZSTK474 ZSTK-474 CHEMBL586701
PIK3CA GuideToPharmacologyInteractions inhibitor AMG319 AMG-319 CHEMBL3545048
PIK3CA MyCancerGenome inhibitor BKM120 BUPARLISIB CHEMBL2017974
PIK3CA ClearityFoundationBiomarkers BYL719 ALPELISIB CHEMBL2396661
PIK3CA NCI I3C INDOLE-3-CARBINOL CHEMBL155625
PIK3CA CKB GDC-0941 PICTILISIB CHEMBL521851
PIK3CA CKB Navitoclax NAVITOCLAX CHEMBL443684
PIK3CA CIViC PICTILISIB PICTILISIB CHEMBL521851
PIK3CA ChemblInteractions inhibitor SF-1126 SF-1126 CHEMBL2326966
PIK3CA ClearityFoundationBiomarkers DS-7423 DS-7423 CHEMBL3545248
PIK3CA GuideToPharmacologyInteractions allosteric modulator PIK-108
PIK3CA CKB Neratinib NERATINIB CHEMBL180022
PIK3CA CGI Cetuximab CETUXIMAB CHEMBL1201577
PIK3CA GuideToPharmacologyInteractions inhibitor AZD8186 AZD-8186 CHEMBL3545424
PIK3CA CKB DS-7423 DS-7423 CHEMBL3545248
PIK3CA OncoKB Copanlisib COPANLISIB CHEMBL3218576
PIK3CA NCI SERM
PIK3CA CKB ASN003
PIK3CA CIViC PP242
PIK3CA CKB AZD6482 AZD-6482 CHEMBL2165191
PIK3CA CIViC BYL719 (ALPELISIB)
PIK3CA MyCancerGenomeClinicalTrial inhibitor PX-866 SONOLISIB CHEMBL411907
PIK3CA CKB AZD5363 AZD-5363 CHEMBL2178577
PIK3CA CKB GDC-0980 APITOLISIB CHEMBL1922094
PIK3CA CKB Radiotherapy
PIK3CA CKB Palbociclib PALBOCICLIB CHEMBL189963
PIK3CA CKB LY2780301 LY-2780301 CHEMBL3545134
PIK3CA NCI RAS INHIBITOR
PIK3CA OncoKB AZD5363 AZD-5363 CHEMBL2178577
PIK3CA NCI HGF
PIK3CA CIViC EVEROLIMUS EVEROLIMUS CHEMBL1908360
PIK3CA CKB Tamoxifen TAMOXIFEN CHEMBL83
PIK3CA CKB Trametinib TRAMETINIB CHEMBL2103875
PIK3CA NCI RAPAMYCIN SIROLIMUS CHEMBL413
PIK3CA CKB TGX-221
PIK3CA MyCancerGenome inhibitor GDC-0032 TASELISIB CHEMBL2387080
PIK3CA ChemblInteractions inhibitor PILARALISIB PILARALISIB (CHEMBL3360203) CHEMBL3360203
PIK3CA ChemblInteractions inhibitor PWT-33587 PWT-33587 CHEMBL3545006
PIK3CA ChemblInteractions inhibitor RECILISIB RECILISIB CHEMBL2219421
PIK3CA CIViC CETUXIMAB CETUXIMAB CHEMBL1201577
PIK3CA CIViC LAPATINIB LAPATINIB CHEMBL554
PIK3CA CKB CUDC-907 CUDC-907 CHEMBL3545052
PIK3CA CKB VS-5584 VS-5584 CHEMBL1079593
PIK3CA CKB Lapatinib LAPATINIB CHEMBL554
PIK3CA CKB Selumetinib SELUMETINIB CHEMBL1614701
PIK3CA CKB GSK2126458 OMIPALISIB CHEMBL1236962
PIK3CA NCI SELECTIVE ESTROGEN RECEPTOR MODULATOR
PIK3CA OncoKB Letrozole LETROZOLE CHEMBL1444
PIK3CA CKB GSK1059615 GSK-1059615 CHEMBL3544966
PIK3CA ChemblInteractions inhibitor PA-799 PA-799 CHEMBL1684984
PIK3CA CKB ARQ092 ARQ-092 CHEMBL3545422
PIK3CA CKB BGJ398 INFIGRATINIB CHEMBL1852688
PIK3CA ChemblInteractions inhibitor TASELISIB TASELISIB CHEMBL2387080
PIK3CA MyCancerGenome inhibitor XL147 PILARALISIB (CHEMBL3218575) CHEMBL3218575
PIK3CA ChemblInteractions inhibitor VS-5584 VS-5584 CHEMBL1079593
PIK3CA OncoKB MLN0128 INK-128 CHEMBL3545056
PIK3CA TdgClinicalTrial RIGOSERTIB RIGOSERTIB CHEMBL1241855
PIK3CA CKB Cisplatin
PIK3CA ChemblInteractions inhibitor COPANLISIB COPANLISIB CHEMBL3218576
PIK3CA GuideToPharmacologyInteractions inhibitor PI 3-KG INHIBITOR II CHEMBL1231533 CHEMBL1231533
PIK3CA CIViC PERIFOSINE PERIFOSINE CHEMBL372764
PIK3CA ChemblInteractions inhibitor PF-04691502 PF-04691502 CHEMBL1234354
PIK3CA ChemblInteractions inhibitor SONOLISIB SONOLISIB CHEMBL411907
PIK3CA ChemblInteractions inhibitor PKI-179 PKI-179 CHEMBL1258517
PIK3CA MyCancerGenome inhibitor GDC-0980 APITOLISIB CHEMBL1922094
PIK3CA CKB Demcizumab DEMCIZUMAB CHEMBL2109384
PIK3CA NCI FLAVOPIRIDOL ALVOCIDIB CHEMBL428690
PIK3CA NCI PKC412 MIDOSTAURIN CHEMBL608533
PIK3CA ChemblInteractions inhibitor CUDC-907 CUDC-907 CHEMBL3545052
PIK3CA CKB P7170 Panulisib CHEMBL3545322
PIK3CA ClearityFoundationBiomarkers GSK2126458 OMIPALISIB CHEMBL1236962
PIK3CA CKB MLN0128 INK-128 CHEMBL3545056
PIK3CA CancerCommons inhibitor BKM120 BUPARLISIB CHEMBL2017974
PIK3CA OncoKB Serabelisib YOHIMBINE CHEMBL15245
PIK3CA ChemblInteractions inhibitor INK-1117 INK-1117 CHEMBL3545055
PIK3CA NCI IL-2
PIK3CA CKB Bevacizumab BEVACIZUMAB CHEMBL1201583
PIK3CA MyCancerGenome inhibitor GSK2636771 GSK-2636771 CHEMBL3188551
PIK3CA CKB PKI-179 PKI-179 CHEMBL1258517
PIK3CA ClearityFoundationBiomarkers BAY80-6946 COPANLISIB CHEMBL3218576
PIK3CA CIViC PALBOCICLIB (PD0332991) PALBOCICLIB CHEMBL189963
PIK3CA CKB Idelalisib IDELALISIB CHEMBL2216870
PIK3CA ChemblInteractions inhibitor LY-3023414 LY-3023414 CHEMBL3544999
PIK3CA CIViC TEMSIROLIMUS TEMSIROLIMUS CHEMBL1201182
PIK3CA CIViC AZD5363 AZD-5363 CHEMBL2178577
PIK3CA NCI THEAFLAVINS
PIK3CA CIViC IDELALISIB IDELALISIB CHEMBL2216870
PIK3CA NCI PTHRP
PIK3CA CKB GSK2334470 CHEMBL1765740 CHEMBL1765740
PIK3CA CKB Doxil
PIK3CA CIViC CISPLATIN
PIK3CA GuideToPharmacologyInteractions inhibitor LY 294002 LY-294002 CHEMBL98350
PIK3CA GuideToPharmacologyInteractions inhibitor ECF309
PIK3CA ClearityFoundationBiomarkers PF-05212384 GEDATOLISIB CHEMBL592445
PIK3CA ClearityFoundationBiomarkers ZSTK474 ZSTK-474 CHEMBL586701
PIK3CA NCI RALOXIFENE RALOXIFENE CHEMBL81
PIK3CA GuideToPharmacologyInteractions inhibitor PIK-75
PIK3CA ChemblInteractions inhibitor DACTOLISIB DACTOLISIB CHEMBL1879463
PIK3CA CKB Ponatinib PONATINIB CHEMBL1171837
PIK3CA GuideToPharmacologyInteractions inhibitor CH5132799 PA-799 CHEMBL1684984
PIK3CA CIViC ANTI-EGFR MONOCLONAL ANTIBODY
PIK3CA ClearityFoundationBiomarkers TEMSIROLIMUS TEMSIROLIMUS CHEMBL1201182
PIK3CA CKB BAY1125976 BAY-1125976 CHEMBL3545049
PIK3CA CKB Sirolimus SIROLIMUS CHEMBL413
PIK3CA CKB GSK2141795 UPROSERTIB CHEMBL3137336
PIK3CA MyCancerGenome inhibitor PI-103 PI-103 CHEMBL573339
PIK3CA CKB Alpelisib ALPELISIB CHEMBL2396661
PIK3CA GuideToPharmacologyInteractions inhibitor APITOLISIB APITOLISIB CHEMBL1922094
PIK3CA ChemblInteractions inhibitor RG-7666 RG-7666 CHEMBL3545324
PIK3CA CKB Doxorubicin DOXORUBICIN CHEMBL53463
PIK3CA CKB LY294002 LY-294002 CHEMBL98350
PIK3CA CKB AT-7867 CHEMBL428462 CHEMBL428462
PIK3CA GuideToPharmacologyInteractions inhibitor BGT-226
PIK3CA NCI SULINDAC SULINDAC CHEMBL15770
PIK3CA NCI CAMPTOTHECIN CAMPTOTHECIN CHEMBL65
PIK3CA GuideToPharmacologyInteractions inhibitor TASELISIB TASELISIB CHEMBL2387080
PIK3CA CKB WEHI-539
PIK3CA CKB GDC-0032 TASELISIB CHEMBL2387080
PIK3CA CKB Fluorouracil FLUOROURACIL CHEMBL185
PIK3CA MyCancerGenome inhibitor PKI-587 GEDATOLISIB CHEMBL592445
PIK3CA ChemblInteractions inhibitor ZSTK-474 ZSTK-474 CHEMBL586701
PIK3CA GuideToPharmacologyInteractions inhibitor BUPARLISIB BUPARLISIB CHEMBL2017974
PIK3CA CancerCommons inhibitor BEZ235 DACTOLISIB CHEMBL1879463
PIK3CA CKB YM-024
PIK3CA CKB PKI-402 CHEMBL589258 CHEMBL589258
PIK3CA CIViC PI3K INHIBITOR
PIK3CA ChemblInteractions inhibitor BGT-226 BGT-226 (CHEMBL3545096) CHEMBL3545096
PIK3CA CKB Vistusertib BENZONATATE CHEMBL1374379
PIK3CA CKB Paclitaxel PACLITAXEL CHEMBL428647
PIK3CA GuideToPharmacologyInteractions inhibitor LENIOLISIB
PIK3CA GuideToPharmacologyInteractions inhibitor PQR309
PIK3CA TdgClinicalTrial SF1126 SF-1126 CHEMBL2326966
PIK3CA CKB FOLFOX
PIK3CA CKB rigosertib RIGOSERTIB CHEMBL1241855
PIK3CA GuideToPharmacologyInteractions inhibitor PICTILISIB PICTILISIB CHEMBL521851
PIK3CA MyCancerGenomeClinicalTrial inhibitor BYL719 ALPELISIB CHEMBL2396661
PIK3CA NCI STZ STREPTOZOTOCIN CHEMBL1651906
PIK3CA NCI HERBIMYCIN A HERBIMYCIN CHEMBL479533
PIK3CA CKB Sapanisertib INK-128 CHEMBL3545056
PIK3CA CKB A-443654 A-443654 CHEMBL379300
PIK3CA CKB AZD8055 AZD-8055 CHEMBL1801204
PIK3CA GuideToPharmacologyInteractions inhibitor AZD8835 CANDICIDIN CHEMBL1200647
PIK3CA MyCancerGenome inhibitor XL-765 VOXTALISIB CHEMBL3545366
PIK3CA GuideToPharmacologyInteractions inhibitor OMIPALISIB OMIPALISIB CHEMBL1236962
PIK3CA OncoKB Taselisib TASELISIB CHEMBL2387080
PIK3CA OncoKB Ribociclib Ribociclib CHEMBL3545110
PIK3CA ChemblInteractions inhibitor GSK-1059615 GSK-1059615 CHEMBL3544966
PIK3CA GuideToPharmacologyInteractions inhibitor AZD6482 AZD-6482 CHEMBL2165191
PIK3CA MyCancerGenomeClinicalTrial inhibitor PKI-587 GEDATOLISIB CHEMBL592445
PIK3CA GuideToPharmacologyInteractions inhibitor COMPOUND 28 [PMID: 24387221]
PIK3CA CKB Pertuzumab PERTUZUMAB CHEMBL2007641
PIK3CA MyCancerGenome inhibitor SF1126 SF-1126 CHEMBL2326966
PIK3CA CKB Fulvestrant FULVESTRANT CHEMBL1358
PIK3CA CKB OSI-027 OSI-027 CHEMBL3120215
PIK3CA ChemblInteractions inhibitor APITOLISIB APITOLISIB CHEMBL1922094
PIK3CA GuideToPharmacologyInteractions inhibitor PI-103 PI-103 CHEMBL573339
PIK3CA ChemblInteractions inhibitor VOXTALISIB VOXTALISIB CHEMBL3545366
PIK3CA GuideToPharmacologyInteractions inhibitor ZSTK474 ZSTK-474 CHEMBL586701
PIK3CA GuideToPharmacologyInteractions inhibitor TG-100-115 TG100-115 CHEMBL230011
PIK3CA CKB PI-103 PI-103 CHEMBL573339
PIK3CA MyCancerGenome inhibitor PWT33597
PIK3CA NCI PACLITAXEL PACLITAXEL CHEMBL428647
PIK3CA CKB U0126 U-0126 CHEMBL100473
PIK3CA CIViC RADIATION
PIK3CA CKB Lucitanib LUCITANIB CHEMBL2220486
PIK3CA OncoKB Trastuzumab TRASTUZUMAB CHEMBL1201585
PIK3CA CKB Torin 1 TORIN1 CHEMBL1256459
PIK3CA CKB Carboxyamidotriazole Orotate
PIK3CA CKB ARQ 751
PIK3CA GuideToPharmacologyInteractions inhibitor GEDATOLISIB GEDATOLISIB CHEMBL592445
PIK3CA CKB AZD8835 CANDICIDIN CHEMBL1200647
PIK3CA CKB 5-FU FLUOROURACIL CHEMBL185
PIK3CA ClearityFoundationBiomarkers XL-147
PIK3CA NCI RESVERATROL RESVERATROL CHEMBL165
PIK3CA CKB Letrozole LETROZOLE CHEMBL1444
PIK3CA MyCancerGenomeClinicalTrial inhibitor GSK2126458 OMIPALISIB CHEMBL1236962
PIK3CA CKB SAR245409 VOXTALISIB CHEMBL3545366
PIK3CA CKB ABT-263 NAVITOCLAX CHEMBL443684
PIK3CA CKB Cetuximab CETUXIMAB CHEMBL1201577
PIK3CA MyCancerGenome inhibitor BGJ398
PIK3CA GuideToPharmacologyInteractions inhibitor PILARALISIB PILARALISIB (CHEMBL3360203) CHEMBL3360203
PIK3CA GuideToPharmacologyInteractions inhibitor VS-5584 VS-5584 CHEMBL1079593
PIK3CA CancerCommons inhibitor PX-866 SONOLISIB CHEMBL411907
PIK3CA CKB NVP-AEW541 AEW-541 CHEMBL551064
PIK3CA CIViC CH5132799 PA-799 CHEMBL1684984
PIK3CA GuideToPharmacologyInteractions inhibitor CUDC-907 CUDC-907 CHEMBL3545052
PIK3CA CKB BKM120 BUPARLISIB CHEMBL2017974
PIK3CA OncoKB Everolimus EVEROLIMUS CHEMBL1908360
PIK3CA CIViC BEZ235 (NVP-BEZ235, DACTOLISIB) DACTOLISIB CHEMBL1879463
PIK3CA ChemblInteractions inhibitor DS-7423 DS-7423 CHEMBL3545248
PIK3CA CKB CH5132799 PA-799 CHEMBL1684984
PIK3CA CKB Regorafenib REGORAFENIB CHEMBL1946170
PIK3CA GuideToPharmacologyInteractions inhibitor SERABELISIB YOHIMBINE CHEMBL15245
PIK3CA CGI Everolimus EVEROLIMUS CHEMBL1908360
PIK3CA GuideToPharmacologyInteractions inhibitor PP121 CHEMBL1081312 CHEMBL1081312
PIK3CA CKB Temsirolimus TEMSIROLIMUS CHEMBL1201182
PIK3CA CKB A-1210477
PIK3CA GuideToPharmacologyInteractions inhibitor IDELALISIB IDELALISIB CHEMBL2216870
PIK3CA CKB MLN1117 INK-1117 CHEMBL3545055
PIK3CA GuideToPharmacologyInteractions inhibitor KU-0060648 CHEMBL1086377 CHEMBL1086377
PIK3CA NCI DHEA PRASTERONE CHEMBL90593
PIK3CA CKB Dabrafenib DABRAFENIB CHEMBL2028663
PIK3CA NCI UROKINASE-TYPE PLASMINOGEN ACTIVATOR
PIK3CA GuideToPharmacologyInteractions inhibitor COMPOUND 11J [PMID: 23021994]
PIK3CA ChemblInteractions inhibitor OMIPALISIB OMIPALISIB CHEMBL1236962
PIK3CA CKB Ridaforolimus RIDAFOROLIMUS CHEMBL2103839
PIK3CA MyCancerGenome inhibitor PF-4691502 PF-04691502 CHEMBL1234354
PIK3CA CKB Copanlisib COPANLISIB CHEMBL3218576
PIK3CA NCI BCG
PIK3CA GuideToPharmacologyInteractions inhibitor PF-04691502 PF-04691502 CHEMBL1234354
PIK3CA OncoKB LJM716
PIK3CA OncoKB Olaparib OLAPARIB CHEMBL521686
PIK3CA NCI 17-AAG CHEMBL126955 CHEMBL126955
PIK3CA NCI NSAID
PIK3CA MyCancerGenome inhibitor GDC-0941 PICTILISIB CHEMBL521851
PIK3CA ChemblInteractions inhibitor AZD-6482 AZD-6482 CHEMBL2165191
PIK3CA GuideToPharmacologyInteractions inhibitor WORTMANNIN WORTMANNIN CHEMBL428496
PIK3CA CKB GS-9820 Acalisib CHEMBL3545397
PIK3CA GuideToPharmacologyInteractions inhibitor NEMIRALISIB
PIK3CA CKB Torkinib
PIK3CA CKB PD-0325901 PD-0325901 CHEMBL507361
PIK3CA CKB Gemcitabine GEMCITABINE CHEMBL888
PIK3CA CKB Deguelin DEGUELIN CHEMBL393417
PIK3CA GuideToPharmacologyInteractions inhibitor INK-128 INK-128 CHEMBL3545056
PIK3CA CKB Dasatinib DASATINIB CHEMBL1421
PIK3CA CancerCommons inhibitor BAY80-6946 COPANLISIB CHEMBL3218576
PIK3CA NCI TRAIL
PIK3CA GuideToPharmacologyInteractions inhibitor PI 3-KG INHIBITOR CHEMBL568150 CHEMBL568150
PIK3CA NCI GM-CSF REGRAMOSTIM CHEMBL2107881
PIK3CA MyCancerGenome inhibitor BAY80-6946 COPANLISIB CHEMBL3218576
PIK3CA CKB CCT128930 CHEMBL263664 CHEMBL263664
PIK3CA TdgClinicalTrial PWT33597
PIK3CA NCI ZINC SULFATE ZINC SULFATE CHEMBL1200929
PIK3CA CKB trastuzumab emtansine TRASTUZUMAB EMTANSINE CHEMBL1743082
PIK3CA CKB A66 PHENMETRAZINE CHEMBL1201208
PIK3CA MyCancerGenomeClinicalTrial inhibitor DACTOLISIB DACTOLISIB CHEMBL1879463
PIK3CA OncoKB Fulvestrant FULVESTRANT CHEMBL1358
PIK3CA MyCancerGenome inhibitor PX-866 SONOLISIB CHEMBL411907
PIK3CA MyCancerGenome inhibitor SOPHORETIN QUERCETIN CHEMBL50
PIK3CA CKB BAY1082439 BAY-1082439 CHEMBL3545245
PIK3CA CIViC TRASTUZUMAB TRASTUZUMAB CHEMBL1201585
PIK3CA NCI CARBOPLATIN CARBOPLATIN CHEMBL1351
PIK3CA NCI ANTIANGIOGENIC
PIK3CA MyCancerGenome inhibitor BEZ235 DACTOLISIB CHEMBL1879463
PIK3CA CKB PF-05212384 GEDATOLISIB CHEMBL592445
PIK3CA CKB WYE-125132
PIK3CA OncoKB GDC-0077 PHENMETRAZINE CHEMBL1201208
PIK3CA GuideToPharmacologyInteractions inhibitor ALPELISIB ALPELISIB CHEMBL2396661
PIK3CA CIViC CABOZANTINIB CABOZANTINIB CHEMBL2105717
PIK3CA NCI VINCRISTINE VINCRISTINE CHEMBL90555
PIK3CA NCI DOXORUBICIN DOXORUBICIN CHEMBL53463
PIK3CA CKB BEZ235 DACTOLISIB CHEMBL1879463
PIK3CA ChemblInteractions inhibitor BAY-1082439 BAY-1082439 CHEMBL3545245
PIK3CA CKB Afuresertib AFURESERTIB CHEMBL2219422
PIK3CA CancerCommons inhibitor BYL719 ALPELISIB CHEMBL2396661
PIK3CA CKB Floxuridine FLOXURIDINE CHEMBL917
PIK3CA CancerCommons inhibitor XL765 VOXTALISIB CHEMBL3545366
PIK3CA ClearityFoundationBiomarkers EVEROLIMUS EVEROLIMUS CHEMBL1908360
PIK3CA NCI RETINOID ETRETINATE CHEMBL464
PIK3CA CKB DHM25
PIK3CA CKB Gedatolisib GEDATOLISIB CHEMBL592445
PIK3CA CKB PWT33597
PIK3CA GuideToPharmacologyInteractions inhibitor LY3023414 LY-3023414 CHEMBL3544999
PIK3CA GuideToPharmacologyInteractions inhibitor COMPOUND 82 [PMID: 21332118]
PIK3CA CKB Camptothecin CAMPTOTHECIN CHEMBL65
PIK3CA ChemblInteractions inhibitor WX-037 WX-037 CHEMBL3545385
PIK3CA CKB Venetoclax VENETOCLAX CHEMBL3137309
PIK3CA GuideToPharmacologyInteractions inhibitor QUINOSTATIN
PIK3CA NCI TYROSINE KINASE INHIBITORS
PIK3CA ChemblInteractions inhibitor Puquitinib Puquitinib CHEMBL3545088
PIK3CA ChemblInteractions inhibitor PWT-33579 PWT-33579 CHEMBL3545323
PIK3CA MyCancerGenomeClinicalTrial inhibitor BUPARLISIB HYDROCHLORIDE BUPARLISIB HYDROCHLORIDE CHEMBL2364604
PIK3CA CKB ABT-737 CHEMBL376408 CHEMBL376408
PIK3CA CIViC PANITUMUMAB PANITUMUMAB CHEMBL1201827
PIK3CA ChemblInteractions inhibitor GEDATOLISIB GEDATOLISIB CHEMBL592445
PIK3CA CKB XL147 PILARALISIB (CHEMBL3218575) CHEMBL3218575
PIK3CA CIViC MK-2206 MK-2206 CHEMBL1079175
PIK3CA GuideToPharmacologyInteractions inhibitor IPI549 OXAZEPAM CHEMBL568
PIK3CA CKB BYL719 ALPELISIB CHEMBL2396661
PIK3CA ChemblInteractions inhibitor BUPARLISIB BUPARLISIB CHEMBL2017974
PIK3CA CKB MK2206 MK-2206 CHEMBL1079175
PIK3CA GuideToPharmacologyInteractions inhibitor DACTOLISIB DACTOLISIB CHEMBL1879463
PIK3CA ChemblInteractions inhibitor Panulisib Panulisib CHEMBL3545322
PIK3CA CKB PD98509
PIK3CA CancerCommons inhibitor SAR260301 SAR-260301 CHEMBL3545008
PIK3CA CKB Metformin METFORMIN CHEMBL1431
PIK3CA CKB Vemurafenib VEMURAFENIB CHEMBL1229517
PIK3CA MyCancerGenomeClinicalTrial inhibitor BAY80-6946 COPANLISIB CHEMBL3218576
PIK3CA NCI SURAMIN SURAMIN CHEMBL265502
PIK3CA CKB Capecitabine CAPECITABINE CHEMBL1773
PIK3CA ClearityFoundationBiomarkers XL765 VOXTALISIB CHEMBL3545366
PIK3CA CKB Everolimus EVEROLIMUS CHEMBL1908360
PIK3CA ClearityFoundationBiomarkers NVP-BEZ235 DACTOLISIB CHEMBL1879463
PIK3CA CKB Pimasertib PIMASERTIB CHEMBL2107832
PIK3CA MyCancerGenome inhibitor BYL719 ALPELISIB CHEMBL2396661
PIK3CA CKB PF-04691502 PF-04691502 CHEMBL1234354
PIK3CA CIViC TASELISIB (GDC-0032)
PIK3CA NCI MILTEFOSINE MILTEFOSINE CHEMBL125
PIK3CA NCI QUERCETIN QUERCETIN CHEMBL50
PIK3CA CGI Trastuzumab TRASTUZUMAB CHEMBL1201585
PIK3CA TdgClinicalTrial XL765 VOXTALISIB CHEMBL3545366
PIK3CA CKB AT13148 AT-13148 CHEMBL3544960
PIK3CA ChemblInteractions inhibitor ALPELISIB ALPELISIB CHEMBL2396661
PIK3CA CKB Irinotecan IRINOTECAN CHEMBL481
PIK3CA CKB CGM097
PIK3CA CKB MSC2363318A MSC-2363318A CHEMBL3545003
PIK3CA CKB PW12
PIK3CA NCI 17-ALLYL-AMINOGELDANAMYCIN CHEMBL126955 CHEMBL126955
PIK3CA GuideToPharmacologyInteractions inhibitor GDC-0077 PHENMETRAZINE CHEMBL1201208
PIK3CA CKB CC-223 CC-223 CHEMBL3545151
PIK3CA CKB cobimetinib COBIMETINIB CHEMBL2146883
PIK3CA NCI CPT-11 IRINOTECAN CHEMBL481
PIK3CA OncoKB Buparlisib BUPARLISIB CHEMBL2017974
PIK3CA NCI IL-11
PIK3CA CKB Trastuzumab TRASTUZUMAB CHEMBL1201585
PIK3CA OncoKB ASN003
PIK3CA CKB Sorafenib SORAFENIB CHEMBL1336
PIK3CA CKB PF-4989216
PIK3CA CKB TAK-733 TAK-733 CHEMBL1615025
PIK3CA CKB LY3023414 LY-3023414 CHEMBL3544999
PIK3CA CKB PX-866 SONOLISIB CHEMBL411907
PIK3CA CKB Bortezomib BORTEZOMIB CHEMBL325041
PIK3CA CKB Carboplatin CARBOPLATIN CHEMBL1351
PIK3CA ChemblInteractions inhibitor PICTILISIB PICTILISIB CHEMBL521851
PIK3CA OncoKB Alpelisib ALPELISIB CHEMBL2396661
PIK3CA CKB Ipatasertib IPATASERTIB CHEMBL2177390
PIK3CA ClearityFoundationBiomarkers PF-04691502 PF-04691502 CHEMBL1234354
PIK3CA CKB Topotecan TOPOTECAN CHEMBL84
PIK3CA CIViC RIBOCICLIB Ribociclib CHEMBL3545110
PIK3CA ChemblInteractions inhibitor MLN-1117 MLN-1117 CHEMBL3545379
PIK3CA GuideToPharmacologyInteractions inhibitor DUVELISIB DUVELISIB CHEMBL3039502
Oncogenic Pathways help
Oncogenic Pathways
Loading...
Oncogenic Pathways
Interaction Networks help
Legend:
  • Phenotype
  • Protein
  • Drug
Loading...

Select a gene to see its drug/phenotype/protein interactions

Reactome Pathways help

All significant pathways (p<0.05) in the selected cohort are presented in the Voronoi interactive plot, with colour intensity representing the number of patients affected
Click here to show visualisation below or here to open the visualisation in a new window

There are patients available from the BCN Biobank that match the selected/a subset of the criteria. Explore the data available for these patients using our Cohort Browser.

Researchers can request samples from BCNB website to support their research activities.

*Based on your filtering criteria you can view the number of available patients and associated samples in BCNB

In order to apply for samples, please use the BCNB Request System to submit an Expression of interest (EOI) form.

If you require further details please contact us at tissue.bank@breastcancernow.org

Patient ID Age at Diagnosis Sex Survival Status Survival Time Follow up Recurrence Type Stage
DO228246 26 female deceased 1.23 relapse distant recurrence_metastasis 3
DO228247 33 female deceased 9.74 relapse distant recurrence_metastasis 3
DO228256 29 female alive 8.72 complete remission NA 2
DO228260 32 female alive 11.41 complete remission NA 2
DO228262 33 female alive 14.66 complete remission NA 2
DO228266 33 female deceased 14.27 relapse distant recurrence_metastasis 2
DO228268 35 female alive 19.17 complete remission NA 2
DO228272 32 female alive 15.56 complete remission NA 2
DO228276 32 female alive 17.39 relapse local recurrence and distant metastasis 2
DO228283 33 female alive 19.53 relapse local recurrence and distant metastasis 3
DO228290 31 female alive 16.09 complete remission NA 2
DO228293 28 female alive 16.36 complete remission NA 2
DO228295 31 female deceased 9.86 relapse distant recurrence_metastasis 2
DO228300 35 female alive 3.59 complete remission NA 2
DO228307 35 female alive 18.58 relapse distant recurrence_metastasis 2
DO228310 33 female deceased 0.58 complete remission NA 2
DO228319 35 female alive 17.78 complete remission NA 1
DO228321 35 female deceased 16.16 relapse distant recurrence_metastasis 2
DO228332 33 female alive 18.01 complete remission NA 2
DO228340 34 female deceased 3.96 complete remission NA 3
DO228350 34 female alive 11.57 complete remission NA 1
DO228356 33 female deceased 14.07 relapse distant recurrence_metastasis 2
DO228383 30 female alive 14.99 complete remission NA 2
DO228404 29 female alive 14.09 complete remission NA 1
DO228409 31 female alive 16.67 complete remission NA 1
DO228423 34 female alive 15.59 complete remission NA 2
DO228426 35 female alive 15.57 complete remission NA 2
DO228427 31 female alive 15.06 complete remission NA 2
DO228430 31 female alive 17.52 complete remission NA 1
DO228431 32 female alive 10.99 complete remission NA 2
DO228433 34 female alive 7.27 complete remission NA 3
DO228439 33 female alive 6.96 complete remission NA 1
DO228441 29 female deceased 0.55 complete remission NA 1
DO228449 27 female alive 18.46 complete remission NA 2
DO228452 32 female deceased 5.1 relapse distant recurrence_metastasis 2
DO228453 34 female alive 15.67 complete remission NA 0
DO228455 34 female alive 11.74 complete remission NA 1
DO228460 25 female alive 12.76 complete remission NA 2
DO228471 28 female alive 6.89 complete remission NA 2
DO228477 33 female alive 8.25 complete remission NA 3
DO228479 27 female alive 7.48 complete remission NA 2
DO228483 34 female alive 7.52 complete remission NA 0
DO228488 30 female alive 3.74 complete remission NA 2
DO228499 29 female alive 1.07 complete remission NA 1
DO228502 27 female alive 0.62 complete remission NA 1
DO228506 32 female alive 1.84 complete remission NA 1
DO228509 33 female alive 1.42 complete remission NA 1
DO228516 35 female alive 1.69 complete remission NA 2
DO228521 32 female alive 1.08 complete remission NA 1
DO229483 34 female alive 1.13 complete remission NA 0

About us

  • Contact us
  • Careers

Information

  • Privacy policy
  • Terms and conditions
  • Your feedback and complaints
  • Medical disclaimer

News and updates

Keep in touch about news, events and how you can get involved.

Stay in touch
  • X
  • LinkedIn
  • Facebook
  • Instagram

  • Fundraising regulator logo

© 2025 Breast Cancer Now

Breast Cancer Now is a company limited by guarantee registered in England (9347608) and a charity registered in England and Wales (1160558), Scotland (SC045584) and Isle of Man (1200). Registered Office: 6th Floor, The White Chapel Building, 10 Whitechapel High Street, London, England, E1 8QS.